The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Where do bispecific antibodies fit into the large cell lymphoma treatment landscape?
Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, discusses the emergence of bispecific antibodies as a preferred treatment option for patients with large cell lymphoma who have experienced progression after CAR T-cell therapy. He highlights promising efficacy data from recent studies, including those involving second-line therapy and combinations with frontline chemoimmunotherapy, which show potential for mitigating cytokine release syndrome (CRS) risks. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’ve now had bispecific antibodies approved for about a year and a half in the third-line setting and beyond in large cell lymphoma. And I think what we see there is they’re really taking shape as the preferred option for patients who have progression after CAR T-cell therapy. They really represent, I think, the best therapy option for those patients. What we’re starting to see now is more of a shift of bispecifics in the earlier lines of therapy...
We’ve now had bispecific antibodies approved for about a year and a half in the third-line setting and beyond in large cell lymphoma. And I think what we see there is they’re really taking shape as the preferred option for patients who have progression after CAR T-cell therapy. They really represent, I think, the best therapy option for those patients. What we’re starting to see now is more of a shift of bispecifics in the earlier lines of therapy. So this summer we saw the STARGLO data. That looks really exciting for patients that are receiving second-line therapy, they’re transplant-ineligible, perhaps even CAR-T ineligible. The efficacy data looks really good. And then we’re starting to see combinations of bispecific antibodies with frontline chemoimmunotherapy. And we’ve seen some early signal from dose escalation studies that looks very promising and also looks to be able to mitigate some of the CRS risk by combining with chemotherapy.
Read more...
